MedTrace Logo

Phase 1-2 Vatalanib and Gemcitabine in Advanced Pancreatic Cancer

NCT00185588 · Status: COMPLETED · Phase: PHASE1/PHASE2 · Type: INTERVENTIONAL · Enrollment: 33

Last updated 2014-09-15

Study results available
· View outcomes & findings →

Summary

The purpose of the study is to determine the optimal safe and tolerable dose of gemcitabine in combination with once daily or twice daily dose of PTK/ZK in patients with unresectable pancreatic cancer. The Phase II part of this study planned to determine the antitumor activity of this regimen and its effectiveness of preventing tumor growth and spread.

Conditions

Interventions

DRUG

Vatalanib

Vatalanib 250 mg PO Q12 hours x 7 days, 8th day forward 500 mg PO Q12 hours

DRUG

Gemcitabine

850 mg/m2

Sponsors & Collaborators

  • Novartis

    collaborator INDUSTRY

  • George Albert Fisher

    lead OTHER

Principal Investigators

  • George Albert Fisher M.D. Ph.D. · Stanford University

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2004-10-31
Primary Completion
2009-01-31
Completion
2009-12-31

Countries

  • United States

Study Locations

More Related Trials

Entities

Drugs
Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00185588 on ClinicalTrials.gov